Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Mutations and transient conformational movements of the receptor binding domain (RBD)
that make neutralizing epitopes momentarily unavailable present immune escape routes for …

Waves of SARS-CoV-2 infection have resulted from the emergence of viral variants with
neutralizing antibody resistance mutations. Simultaneously, repeated antigen exposure has …

Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2
on host cells is essential for viral entry. RBD is the dominant target for neutralizing …

Prevention of viral escape and increased coverage against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal …

Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. The
determinants for selecting antibody combinations and the mechanism that antibody cocktails …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

The spike protein receptor-binding domain (RBD) of SARS-CoV-2 is the molecular target for
many vaccines and antibody-based prophylactics aimed at bringing COVID-19 under …

Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …

The worldwide spread of COVID-19 highlights the need for an efficient approach to rapidly
develop therapeutics and prophylactics against SARS-CoV-2. The SARS-CoV-2 spike …